Evidence map›Paper›PMID 35171006›Full record

ArticleMicrobiology spectrum2022

SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.

Steven J Drews, Queenie Hu, Reuben Samson, Kento T Abe, Bhavisha Rathod, Karen Colwill, Anne-Claude Gingras, Qi-Long Yi, Sheila F O'Brien

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Steven J DrewsDepartment of Microbiology, Canadian Blood Servicesgrid.423370.1, Edmonton, Alberta, Canada.ORCID 0000-0003-2519-1109
Queenie HuLunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
Reuben SamsonLunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
Kento T AbeLunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
Bhavisha RathodLunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
Karen ColwillLunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
Qi-Long YiEpidemiology and Surveillance, Canadian Blood Servicesgrid.423370.1, Ottawa, Ontario, Canada.
Sheila F O'BrienEpidemiology and Surveillance, Canadian Blood Servicesgrid.423370.1, Ottawa, Ontario, Canada.
Lunenfeld-Tanenbaum Research Institute · CAUniversity of Toronto · CAUniversity of Ottawa · CAUniversity of Alberta · CA

Funding

Alberta Innovates G2020000360 DrewsGouvernement du Canada | Canadian Institutes of Health Research (IRSC) VR2-172723
6 · The paper itself

Abstract

This study attempted to understand the levels of neutralizing titers and the breadth of antibody protection against wild-type and variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Canadian blood donors during the first 3 months of 2021. During this period, it is unlikely that many of the blood donors had received a second dose, since vaccine rollout had not yet ramped up, and less than 2% of the Canadian population had received a second dose of vaccine. A repeated cross-sectional design was used. A random cross-sectional sampling of all available Canadian Blood Services retention samples (

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralBlood DonorsCanadaCOVID-19COVID-19 VaccinesCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeutralization TestsAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesneutralizing antibodiesnucleocapsidreceptor-binding domainSARS-CoV-2 antibodyspikevariants of concernvirus-like particles

Identifiers

PMID35171006
PMCPMC8849073
OpenAlexW4212912712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.